Cencora

COR

Market cap $71.6B

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here is how Cencora (COR) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cencora is rated a Buy, with a target price of $392, driven by strong fundamentals and sector leadership. COR's stable business model, high cash flows, low debt, and shareholder-friendly policies make it attractive for conservative, long-term investors. Recent earnings showed double-digit profit growth, robust revenue from specialty drugs, and high predictability, supporting management's optimistic forecasts.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Cencora, Inc. ( COR ) Q4 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Bennett Murphy - Senior VP, Head of Investor Relations & Treasury Robert Mauch - President, CEO & Director James Cleary - Executive VP & CFO Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Michael Cherny - Leerink Partners LLC, Research Division Charles Rhyee - TD Cowen, Research Division Erin Wilson Wright - Morgan Stanley, Research Division Allen Lutz - BofA Securities, Research Division Eric Percher - Nephron Research LLC Steven Valiquette - Mizuho Securities USA LLC, Research Division George Hill - Deutsche Bank AG, Research Division Kevin Caliendo - UBS Investment Bank, Research Division Daniel Grosslight - Citigroup Inc., Research Division Presentation Operator Hello, everyone, and thank you for joining the Cencora Fiscal 2025 Fourth Quarter and Full Year Results Call. My name is Lucy, and I'll be coordinating your call today.

Cencora's Q4 results top estimates with 15% EPS growth and stronger margins, as GLP-1 demand and the RCA acquisition fuel solid segment gains.

Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.